{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:36:11Z","timestamp":1778754971923,"version":"3.51.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/DTP-FTO\/1489\/2014 \u2013 POCI-01-0145-FEDER-016537"],"award-info":[{"award-number":["PTDC\/DTP-FTO\/1489\/2014 \u2013 POCI-01-0145-FEDER-016537"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["DL57\/2016\/CP1334\/CT0006"],"award-info":[{"award-number":["DL57\/2016\/CP1334\/CT0006"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00204-020-02874-4","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T14:02:45Z","timestamp":1599487365000},"page":"4067-4084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations"],"prefix":"10.1007","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-2756","authenticated-orcid":false,"given":"Vera Marisa","family":"Costa","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-1264","authenticated-orcid":false,"given":"Jo\u00e3o Paulo","family":"Capela","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-023X","authenticated-orcid":false,"given":"Joana R.","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Rute P.","family":"Eleut\u00e9rio","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia R. S.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Lu\u00eds","family":"Dores-Sousa","sequence":"additional","affiliation":[]},{"given":"Rui A.","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Lourdes Bastos","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Alberto","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Remi\u00e3o","sequence":"additional","affiliation":[]},{"given":"M. Gabriela","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Kurt J.","family":"Varner","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-3494","authenticated-orcid":false,"given":"F\u00e9lix","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"issue":"2","key":"2874_CR1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.drudis.2015.09.012","volume":"21","author":"Y Aghazadeh","year":"2016","unstructured":"Aghazadeh Y, Papadopoulos V (2016) The role of the 14-3-3 protein family in health, disease, and drug development. Drug Discov Today 21(2):278\u2013287","journal-title":"Drug Discov Today"},{"issue":"1","key":"2874_CR2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.20747","volume":"59","author":"E Bernitsas","year":"2006","unstructured":"Bernitsas E, Wei W, Mikol DD (2006) Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann Neurol 59(1):206\u2013209","journal-title":"Ann Neurol"},{"issue":"33","key":"2874_CR3","doi-asserted-by":"crossref","first-page":"25231","DOI":"10.1074\/jbc.275.33.25231","volume":"275","author":"MP Boland","year":"2000","unstructured":"Boland MP, Fitzgerald KA, O'Neill LAJ (2000) Topoisomerase II Is required for mitoxantrone to signal nuclear factor \u03baB activation in HL60 Cells. J Biol Chem 275(33):25231\u201325238","journal-title":"J Biol Chem"},{"issue":"4","key":"2874_CR4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","volume":"14","author":"DA Brown","year":"2017","unstructured":"Brown DA, Perry JB, Allen ME et al (2017) Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol 14(4):238\u2013250","journal-title":"Nat Rev Cardiol"},{"issue":"20","key":"2874_CR5","first-page":"4850","volume":"53","author":"P Canal","year":"1993","unstructured":"Canal P, Attal M, Chatelut E et al (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 53(20):4850\u20134854","journal-title":"Cancer Res"},{"issue":"3","key":"2874_CR6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.neuroscience.2006.01.007","volume":"139","author":"JP Capela","year":"2006","unstructured":"Capela JP, Ruscher K, Lautenschlager M et al (2006) Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia. Neuroscience 139(3):1069\u20131081","journal-title":"Neuroscience"},{"key":"2874_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-62703-290-2_7","volume":"979","author":"FK-M Chan","year":"2013","unstructured":"Chan FK-M, Moriwaki K, De Rosa MJ (2013) Detection of necrosis by release of lactate dehydrogenase activity. Methods Mol Biol 979:65\u201370","journal-title":"Methods Mol Biol"},{"issue":"12","key":"2874_CR8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/ene.13748","volume":"25","author":"N Chartier","year":"2018","unstructured":"Chartier N, Epstein J, Soudant M et al (2018) Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study. Eur J Neurol 25(12):1439\u20131445","journal-title":"Eur J Neurol"},{"issue":"3","key":"2874_CR9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/mi.7.3.6","volume":"7","author":"Y Chen","year":"2007","unstructured":"Chen Y, Jungsuwadee P, Vore M, Butterfield DA (2007) Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 7(3):147\u2013156","journal-title":"Mol Interv"},{"issue":"6","key":"2874_CR10","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.95.6.2979","volume":"95","author":"WC Claycomb","year":"1998","unstructured":"Claycomb WC, Lanson NAJ, Stallworth BS et al (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95(6):2979\u20132984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2874_CR11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0277-5379(84)90215-3","volume":"20","author":"RE Coleman","year":"1984","unstructured":"Coleman RE, Maisey MN, Knight RK, Rubens RD (1984) Mitoxantrone in advanced breast cancer\u2013a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 20(6):771\u2013776","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"14","key":"2874_CR12","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.1074\/jbc.M310106200","volume":"279","author":"G Corna","year":"2004","unstructured":"Corna G, Santambrogio P, Minotti G, Cairo G (2004) Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279(14):13738\u201313745","journal-title":"J Biol Chem"},{"issue":"1","key":"2874_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/tx8002577","volume":"22","author":"VM Costa","year":"2009","unstructured":"Costa VM, Ferreira LM, Branco PS et al (2009a) Cross-functioning between the extraneuronal monoamine transporter and multidrug resistance protein 1 in the uptake of adrenaline and export of 5-(glutathion-S-yl)adrenaline in rat cardiomyocytes. Chem Res Toxicol 22(1):129\u2013135","journal-title":"Chem Res Toxicol"},{"key":"2874_CR14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tox.2008.12.010","volume":"257","author":"VM Costa","year":"2009","unstructured":"Costa VM, Silva R, Ferreira R et al (2009b) Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes. Toxicology 257:70\u201379","journal-title":"Toxicology"},{"issue":"1\u20132","key":"2874_CR15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0009-8981(03)00003-2","volume":"329","author":"I Dalle-Donne","year":"2003","unstructured":"Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003) Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329(1\u20132):23\u201338","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2874_CR16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1582-4934.2006.tb00407.x","volume":"10","author":"I Dalle-Donne","year":"2006","unstructured":"Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A (2006) Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 10(2):389\u2013406","journal-title":"J Cell Mol Med"},{"issue":"9","key":"2874_CR17","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00204-016-1759-y","volume":"90","author":"RM Damiani","year":"2016","unstructured":"Damiani RM, Moura DJ, Viau CM, Caceres RA, Henriques JA, Saffi J (2016) Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone. Arch Toxicol 90(9):2063\u20132076","journal-title":"Arch Toxicol"},{"key":"2874_CR18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2015.01.006","volume":"329","author":"JL Dores-Sousa","year":"2015","unstructured":"Dores-Sousa JL, Duarte JA, Seabra V, Bastos ML, Carvalho F, Costa VM (2015) The age factor for mitoxantrone\u2019s cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury. Toxicology 329:106\u2013119","journal-title":"Toxicology"},{"issue":"2","key":"2874_CR19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cvr\/cvp107","volume":"83","author":"H Dreger","year":"2009","unstructured":"Dreger H, Westphal K, Weller A et al (2009) Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res 83(2):354\u2013361","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2874_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-9-56","volume":"9","author":"Z-X Du","year":"2009","unstructured":"Du Z-X, Zhang H-Y, Meng X, Guan Y, Wang H-Q (2009) Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer 9(1):56","journal-title":"BMC Cancer"},{"issue":"4","key":"2874_CR21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/bjc.1989.314","volume":"60","author":"SJ Duthie","year":"1989","unstructured":"Duthie SJ, Grant MH (1989) The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. Br J Cancer 60(4):566\u2013571","journal-title":"Br J Cancer"},{"issue":"2","key":"2874_CR22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00174157","volume":"3","author":"G Ehninger","year":"1985","unstructured":"Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL (1985) The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 3(2):109\u2013116","journal-title":"Invest New Drugs"},{"issue":"6","key":"2874_CR23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbabio.2008.03.019","volume":"1777","author":"M Eimre","year":"2008","unstructured":"Eimre M, Paju K, Pelloux S et al (2008) Distinct organization of energy metabolism in HL-1 cardiac cell line and cardiomyocytes. Biochim Biophys Acta 1777(6):514\u2013524","journal-title":"Biochim Biophys Acta"},{"key":"2874_CR24","unstructured":"EMA (2016) Novantrone and associated names. In: Agency EM (ed). https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Novantrone_30\/WC500209683.pdf. Accessed Nov 2019"},{"issue":"5","key":"2874_CR25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 18(5):459\u2013480","journal-title":"Lancet Neurol"},{"key":"2874_CR26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I et al (2018) Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 103:356\u2013387","journal-title":"Eur J Cancer"},{"issue":"5","key":"2874_CR27","doi-asserted-by":"crossref","first-page":"e005897","DOI":"10.1161\/CIRCHEARTFAILURE.118.005897","volume":"12","author":"JP Ferreira","year":"2019","unstructured":"Ferreira JP, Verdonschot J, Collier T et al (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure. Circ Heart Fail 12(5):e005897","journal-title":"Circ Heart Fail"},{"issue":"19","key":"2874_CR28","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1161\/CIRCULATIONAHA.107.670588","volume":"115","author":"BN Finck","year":"2007","unstructured":"Finck BN, Kelly DP (2007) Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 115(19):2540\u20132548","journal-title":"Circulation"},{"issue":"6","key":"2874_CR29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685596","volume":"30","author":"GR Fisher","year":"1992","unstructured":"Fisher GR, Patterson LH (1992) Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Cancer Chemother Pharmacol 30(6):451\u2013458","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2874_CR30","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice C et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017. JAMA Oncol 5(12):1749\u20131768","journal-title":"JAMA Oncol"},{"issue":"2","key":"2874_CR31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40120-018-0112-1","volume":"7","author":"A Ghezzi","year":"2018","unstructured":"Ghezzi A (2018) European and american guidelines for multiple sclerosis treatment. Neurol Ther 7(2):189\u2013194","journal-title":"Neurol Ther"},{"issue":"1","key":"2874_CR32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.CIR.0000043803.20822.D1","volume":"107","author":"JR Gonz\u00e1lez-Juanatey","year":"2003","unstructured":"Gonz\u00e1lez-Juanatey JR, Iglesias MJ, Alcaide C, Pi\u00f1eiro R, Lago F (2003) Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of \u03911-adrenergic blockade. Circulation 107(1):127\u2013131","journal-title":"Circulation"},{"issue":"10","key":"2874_CR33","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","volume":"61","author":"DS Goodin","year":"2003","unstructured":"Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW (2003) The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 61(10):1332\u20131338","journal-title":"Neurology"},{"issue":"15","key":"2874_CR34","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1016\/j.jprot.2012.02.004","volume":"75","author":"S Gratia","year":"2012","unstructured":"Gratia S, Kay L, Michelland S, Seve M, Schlattner U, Tokarska-Schlattner M (2012) Cardiac phosphoproteome reveals cell signaling events involved in doxorubicin cardiotoxicity. J Proteomics 75(15):4705\u20134716","journal-title":"J Proteomics"},{"issue":"6","key":"2874_CR35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0168-8278(01)00037-X","volume":"34","author":"CL Hammond","year":"2001","unstructured":"Hammond CL, Lee TK, Ballatori N (2001) Novel roles for glutathione in gene expression, cell death, and membrane transport of organic solutes. J Hepatol 34(6):946\u2013954","journal-title":"J Hepatol"},{"issue":"3","key":"2874_CR36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12012-019-09554-5","volume":"20","author":"BB Hasinoff","year":"2020","unstructured":"Hasinoff BB, Patel D, Wu X (2020) The role of topoisomerase IIbeta in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane. Cardiovasc Toxicol 20(3):312\u2013320","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"2874_CR37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/1097-0142(19920215)69:4<847::AID-CNCR2820690402>3.0.CO;2-L","volume":"69","author":"OY Hu","year":"1992","unstructured":"Hu OY, Chang SP, Law CK, Jian JM, Chen KY (1992) Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. Cancer 69(4):847\u2013853","journal-title":"Cancer"},{"issue":"1","key":"2874_CR38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.hfc.2017.08.010","volume":"14","author":"MZ Israr","year":"2018","unstructured":"Israr MZ, Heaney LM, Suzuki T (2018) Proteomic Biomarkers of Heart Failure. Heart Fail Clin 14(1):93\u2013107","journal-title":"Heart Fail Clin"},{"key":"2874_CR39","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1101\/pdb.prot4493","volume":"3","author":"S Kasibhatla","year":"2006","unstructured":"Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR (2006) Acridine orange\/ethidium bromide (AO\/EB) staining to detect apoptosis. Cold Spring Harbor Protocols 3:4493","journal-title":"Cold Spring Harbor Protocols"},{"issue":"42","key":"2874_CR40","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/sj.onc.1207936","volume":"23","author":"J Kluza","year":"2004","unstructured":"Kluza J, Marchetti P, Gallego MA et al (2004) Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 23(42):7018\u20137030","journal-title":"Oncogene"},{"issue":"6","key":"2874_CR41","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s10495-005-1540-9","volume":"10","author":"A Koceva-Chy\u0142a","year":"2005","unstructured":"Koceva-Chy\u0142a A, Jedrzejczak M, Skierski J, Kania K, J\u00f3\u017awiak Z (2005) Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis 10(6):1497\u20131514","journal-title":"Apoptosis"},{"key":"2874_CR42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbamcr.2014.11.015","volume":"2","author":"AV Kuznetsov","year":"2015","unstructured":"Kuznetsov AV, Javadov S, Sickinger S, Frotschnig S (2015) Grimm M. H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation. Biochim Biophys Acta 2:276\u2013284","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2874_CR43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265\u2013275","journal-title":"J Biol Chem"},{"issue":"18","key":"2874_CR44","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"YL Lyu","year":"2007","unstructured":"Lyu YL, Kerrigan JE, Lin CP et al (2007) Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67(18):8839\u20138846","journal-title":"Cancer Res"},{"issue":"18","key":"2874_CR45","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","volume":"74","author":"JJ Marriott","year":"2010","unstructured":"Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW (2010) Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 74(18):1463\u20131470","journal-title":"Neurology"},{"issue":"4","key":"2874_CR46","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/med.21476","volume":"38","author":"P Mladenka","year":"2018","unstructured":"Mladenka P, Applova L, Patocka J et al (2018) Comprehensive review of cardiovascular toxicity of drugs and related agents. Med Res Rev 38(4):1332\u20131403","journal-title":"Med Res Rev"},{"key":"2874_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.06.2009.2004","author":"F Paul","year":"2009","unstructured":"Paul F, D\u00f6rr J, W\u00fcrfel J, Vogel HP, Zipp F (2009) Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr.06.2009.2004","journal-title":"BMJ Case Rep"},{"issue":"3","key":"2874_CR48","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","volume":"23","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23(3):630\u2013639","journal-title":"J Clin Oncol"},{"issue":"1","key":"2874_CR49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1006\/abbi.2000.1717","volume":"377","author":"T Reinheckel","year":"2000","unstructured":"Reinheckel T, Ullrich O, Sitte N, Grune T (2000) Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch Biochem Biophys 377(1):65\u201368","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"2874_CR50","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00204-016-1839-z","volume":"91","author":"A Reis-Mendes","year":"2017","unstructured":"Reis-Mendes A, GA S, Carvalho RA et al (2017) Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. Arch Toxicol 91(4):1871\u20131890","journal-title":"Arch Toxicol"},{"issue":"6","key":"2874_CR51","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00204-020-02718-1","volume":"94","author":"D Rodrigues","year":"2020","unstructured":"Rodrigues D, Neves R, Carvalho A, Lourdes Bastos M, Costa V, Carvalho F (2020) In vitro mechanistic studies on \u03b1-amanitin and its putative antidotes. Arch Toxicol 94(6):2061\u20132078","journal-title":"Arch Toxicol"},{"issue":"6","key":"2874_CR52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","volume":"113","author":"VL Roger","year":"2013","unstructured":"Roger VL (2013) Epidemiology of heart failure. Circ Res 113(6):646\u2013659","journal-title":"Circ Res"},{"key":"2874_CR53","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00204-013-1040-6","volume":"87","author":"LG Rossato","year":"2013","unstructured":"Rossato LG, Costa VM, Pinto PG et al (2013a) The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Arch Toxicol 87:1809\u20131820","journal-title":"Arch Toxicol"},{"issue":"4","key":"2874_CR54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12012-013-9224-0","volume":"13","author":"LG Rossato","year":"2013","unstructured":"Rossato LG, Costa VM, Vilas-Boas V et al (2013b) Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells: mitochondrionopathy as a key factor in the cytotoxicity. Cardiovasc Toxicol 13(4):413\u2013425","journal-title":"Cardiovasc Toxicol"},{"issue":"1","key":"2874_CR55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12012-013-9230-2","volume":"14","author":"LG Rossato","year":"2014","unstructured":"Rossato LG, Costa VM, Dallegrave E et al (2014) Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. Cardiovasc Toxicol 14(1):30\u201340","journal-title":"Cardiovasc Toxicol"},{"issue":"8","key":"2874_CR56","first-page":"1641","volume":"66","author":"FC Schell","year":"1982","unstructured":"Schell FC, Yap HY, Blumenschein G, Valdivieso M, Bodey G (1982) Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep 66(8):1641\u20131643","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"2874_CR57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/14740338.4.2.219","volume":"4","author":"K Seiter","year":"2005","unstructured":"Seiter K (2005) Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4(2):219\u2013234","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"2874_CR58","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/echo.13245","volume":"33","author":"AY Shaikh","year":"2016","unstructured":"Shaikh AY, Suryadevara S, Tripathi A et al (2016) Mitoxantrone-induced cardiotoxicity in acute myeloid leukemia-a velocity vector imaging analysis. Echocardiography (Mount Kisco, NY) 33(8):1166\u20131177","journal-title":"Echocardiography (Mount Kisco, NY)"},{"issue":"12","key":"2874_CR59","doi-asserted-by":"crossref","first-page":"e1006584","DOI":"10.1371\/journal.pcbi.1006584","volume":"14","author":"M Shan","year":"2018","unstructured":"Shan M, Dai D, Vudem A, Varner JD, Stroock AD (2018) Multi-scale computational study of the Warburg effect, reverse Warburg effect and glutamine addiction in solid tumors. PLoS Comput Biol 14(12):e1006584","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"2874_CR60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.7326\/0003-4819-105-1-67","volume":"105","author":"TD Shenkenberg","year":"1986","unstructured":"Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105(1):67\u201381","journal-title":"Ann Intern Med"},{"issue":"3","key":"2874_CR61","first-page":"550","volume":"53","author":"NG Shipp","year":"1993","unstructured":"Shipp NG, Dorr RT, Alberts DS, Dawson BV, Hendrix M (1993) Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res 53(3):550\u2013556","journal-title":"Cancer Res"},{"issue":"8","key":"2874_CR62","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.biopha.2013.08.003","volume":"67","author":"AS Soares","year":"2013","unstructured":"Soares AS, Costa VM, Diniz C, Fresco P (2013) Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma. Biomed Pharmacother 67(8):777\u2013789","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2874_CR63","first-page":"243","volume":"33","author":"WC Stanley","year":"1997","unstructured":"Stanley WC, Lopaschuk GD, Hall JL, McCormack JG (1997) Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardio Res 33(2):243\u2013257","journal-title":"Potential Pharmacol Int Cardio Res"},{"issue":"6","key":"2874_CR64","first-page":"1327","volume":"66","author":"JA Stewart","year":"1982","unstructured":"Stewart JA, McCormack JJ, Krakoff IH (1982) Clinical and clinical pharmacologic studies of mitoxantrone. Cancer Treat Rep 66(6):1327\u20131331","journal-title":"Cancer Treat Rep"},{"issue":"11","key":"2874_CR65","first-page":"1255","volume":"70","author":"DJ Stewart","year":"1986","unstructured":"Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, Maroun JA (1986) Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 70(11):1255\u20131261","journal-title":"Cancer Treat Rep"},{"issue":"2","key":"2874_CR66","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/toxsci\/kfr298","volume":"125","author":"A Strigun","year":"2012","unstructured":"Strigun A, Wahrheit J, Niklas J, Heinzle E, Noor F (2012) Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis. Toxicol Sci 125(2):595\u2013606","journal-title":"Toxicol Sci"},{"issue":"11","key":"2874_CR67","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1074\/jbc.M009831200","volume":"276","author":"M Tabata","year":"2001","unstructured":"Tabata M, Tabata R, Grabowski DR, Bukowski RM, Ganapathi MK, Ganapathi R (2001) Roles of NF-\u03baB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma. J Biol Chem 276(11):8029\u20138036","journal-title":"J Biol Chem"},{"issue":"6","key":"2874_CR68","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.ijcard.2013.01.163","volume":"167","author":"G Takemura","year":"2013","unstructured":"Takemura G, Kanoh M, Minatoguchi S, Fujiwara H (2013) Cardiomyocyte apoptosis in the failing heart \u2014 a critical review from definition and classification of cell death. Int J Cardiol 167(6):2373\u20132386","journal-title":"Int J Cardiol"},{"issue":"4","key":"2874_CR69","first-page":"343","volume":"67","author":"DV Unverferth","year":"1983","unstructured":"Unverferth DV, Unverferth BJ, Balcerzak SP, Bashore TA, Neidhart JA (1983) Cardiac evaluation of mitoxantrone. Cancer Treat Rep 67(4):343\u2013350","journal-title":"Cancer Treat Rep"},{"issue":"10","key":"2874_CR70","doi-asserted-by":"crossref","first-page":"e76676","DOI":"10.1371\/journal.pone.0076676","volume":"8","author":"A Vavrova","year":"2013","unstructured":"Vavrova A, Jansova H, Mackova E et al (2013) Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS ONE 8(10):e76676","journal-title":"PLoS ONE"},{"issue":"23","key":"2874_CR71","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/BF01727665","volume":"66","author":"A von Herbay","year":"1988","unstructured":"von Herbay A, D\u00f6rken B, Mall G, K\u00f6rbling M (1988) Cardiac damage in autologous bone marrow transplant patients: an autopsy study Cardiotoxic pretreatment as a major risk factor. Klin Wochenschr 66(23):1175\u20131181","journal-title":"Klin Wochenschr"},{"issue":"3","key":"2874_CR72","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","volume":"18","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Nichols E et al (2019) Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(3):269\u2013285","journal-title":"Lancet Neurol"},{"issue":"12","key":"2874_CR73","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/01.RES.0000252342.61447.a2","volume":"99","author":"X Wang","year":"2006","unstructured":"Wang X, Robbins J (2006) Heart failure and protein quality control. Circ Res 99(12):1315\u20131328","journal-title":"Circ Res"},{"issue":"1","key":"2874_CR74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1582-4934.2002.tb00309.x","volume":"6","author":"C Wojcik","year":"2002","unstructured":"Wojcik C (2002) Regulation of apoptosis by the ubiquitin and proteasome pathway. J Cell Mol Med 6(1):25\u201348","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2874_CR75","first-page":"1303","volume":"66","author":"WR Wynert","year":"1982","unstructured":"Wynert WR, Harvey HA, Lipton A, Schweitzer J, White DS (1982) Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione). Cancer Treat Rep 66(6):1303\u20131306","journal-title":"Cancer Treat Rep"},{"key":"2874_CR76","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.redox.2019.101339","volume":"28","author":"A Young","year":"2020","unstructured":"Young A, Oldford C, Mailloux RJ (2020) Lactate dehydrogenase supports lactate oxidation in mitochondria isolated from different mouse tissues. Redox Biol 28:101339","journal-title":"Redox Biol"},{"issue":"11","key":"2874_CR77","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18(11):1639\u20131642","journal-title":"Nat Med"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02874-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-020-02874-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02874-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T02:47:25Z","timestamp":1668653245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-020-02874-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2874"],"URL":"https:\/\/doi.org\/10.1007\/s00204-020-02874-4","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"19 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest:"}}]}}